Kurome enters into licensing agreements and a cooperative research and development agreement with Cincinnati Children's Hospital Medical Center and the National Institutes of Health's (NIH) National ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 2 min A Hyde Park-based startup spun ...

KUROME THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KME-0584 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) ...

Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, ...

Kurome Therapeutics has raised $15 million to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms. Medicxi and Affinity Asset Advisors co-led the series A round to fund ...

Cincinnati Children’s Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have jointly patented interleukin-1 receptor-associated kinase 1 (IRAK-1) ...

Kurome Therapeutics Inc. has received FDA clearance of its IND for KME-0584, allowing the company to proceed with a phase I trial in relapsed or refractory acute myeloid leukemia (AML) and high-risk ...

No articles found. Kurome Therapeutics, Inc. did not contribute to any primary research papers from Nature Index journals in the current 12 month window.

Entering the clinic in the second half of 2024, KME-0584, an IRAK1/4/panFIt3 Inhibitor is a first in class investigational drug for relapsed/refractory AML and high-risk MDS patients ...

Entering the clinic in the second half of 2024, KME-0584, an IRAK1/4/panFIt3 Inhibitor is a first in class investigational drug for relapsed/refractory AML and high-risk MDS patients CINCINNATI, ...